HCSC Coverage Is a Win for New-Gen Cardiac Telemetry Device

Ten years after the launch of a mobile outpatient cardiac telemetry device from medtech company BioTelemetry, Inc., insurer Health Care Service Corp. (HCSC) has included it in its medical coverage policy. Pennsylvania-based manufacturer BioTelemetry revealed the coverage decision in a February earnings call, saying that the move was the result of a non-stop effort to flip a small holdout of insurers. BioTelemetry says about 95% of payers cover the diagnostic device, and many without step therapy requirements that mandate patients try other devices first.

The mobile outpatient cardiac telemetry (MOCT) device is perhaps one of the most recent medical developments used for diagnosing heart rhythm and rate abnormalities. These problems — the heart pumping too slow or too fast — can cause sudden cardiac arrest, stroke and/or death.

0 Comments
© 2022 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

golden-gate-bridge
September 23

West Coast Public Sector Plan Sponsors Will Coordinate More Closely Through Purchaser Group

READ MORE
remote-patient-monitoring-and-phone
September 23

Spike in Remote Patient Monitoring During Pandemic Is Driven by a Fraction of Providers

READ MORE
humana-headquarter
September 23

Humana Will Buy One Primary Care Group — and Could Snap Up Another

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today